Itron, Inc. - Common Stock (ITRI)
Healthcare › Instruments For Meas & Testing of Electricity & Elec Signals
Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- Trading 20% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 15.7% — good return on equity
Itron, Inc. - Common Stock (ITRI) is a Healthcare company operating in Instruments For Meas & Testing of Electricity & Elec Signals, listed on the NASDAQ , with a market capitalisation of $3.6 billion . Key value metrics: P/E ratio 14.4, P/B ratio 2.26, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Itron, Inc. - Common Stock — Fundamental Analysis Summary
Itron, Inc. - Common Stock (ITRI) is currently trading 20% above its Graham Number of $68.20, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 14.4x.
On financial health, ITRI shows a moderate Piotroski F-Score of 5/9, and solid return on equity of 15.7% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.98.
StockPik's composite Value Score for ITRI is 91/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ITRI reports a moderate gross margin of 37.6% (sector average: 40.1%) and a solid operating margin of 12.7%.
ITRI shows revenue declining at 3% year-over-year, with earnings growing at 26%.